Compounded vials require self-measurement, which adds dosing-error risk not present with fixed-dose pens.
Many compounded products come as multi-dose vials where you draw the dose yourself. Concentrations vary by pharmacy, so “units” on a syringe don’t map cleanly to milligrams. A mismatch between the prescribed dose and the vial concentration can cause accidental overdosing. If unsure, confirm with the prescriber or pharmacy before injecting.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.